Categories: NewsPharmaceutical

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.

HCW Conference Details:

Fireside Chat: Thursday, March 28, 2024, at 8:30 am ET
Speakers: David Domzalski, President and Chief Executive Officer
Iain Stuart, Ph.D., Chief Scientific Officer
Registration: Webcast Link
   

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, include a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

Staff

Recent Posts

Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture

PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…

5 hours ago

Prior to FIFA Club World Cup Kickoff, FC Mother and Omya Launch Landmark Joint Venture to Fund “Life Years” as Part of World Cup of Healing Legacy Project

First-of-its-kind joint venture funds longevity gains and maternal healing through football, creating a new category…

5 hours ago

Personal Safety Tracking Devices Market to Reach USD 1.6 Billion by 2030, Driven by GPS and Bluetooth Advancements | Valuates Reports

BANGALORE, India, June 13, 2025 /PRNewswire/ -- Personal Safety Tracking Devices Market is Segmented by Type…

5 hours ago

Dana Foundation Recognizes Two Neuroscience & Society Champions with Inaugural Awards

Neuroethicist and psychiatrist are recognized for innovation and transformative interdisciplinary work to advance neuroscience's benefits…

5 hours ago

Clear Guide Medical LUMENA™ Featured in SPIE Study on MRI-Guided Interventions

BALTIMORE, June 13, 2025 /PRNewswire/ -- Clear Guide Medical, a leader in AI- and AR-powered…

5 hours ago